Literature DB >> 23397051

Elevated clozapine serum levels in combination with perazine.

M Fischer, S Unterecker, J Deckert, B Pfuhlmann.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23397051     DOI： 10.1007/s00213-013-3007-y

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN： 0033-3158            Impact factor:   4.530


× No keyword cloud information.
  12 in total

1.  Cytochrome P-450 enzymes and FMO3 contribute to the disposition of the antipsychotic drug perazine in vitro.

Authors:  E Störmer; J Brockmöller; I Roots; J Schmider
Journal:  Psychopharmacology (Berl)       Date:  2000-09       Impact factor: 4.530

2.  Perazine elevates clozapine serum levels by inhibiting hepatic metabolism.

Authors:  Gerd Schaller; Andrea Jacobi; Andrea Rotter; Johannes Kornhuber; Thomas Hillemacher
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2009-04-17       Impact factor: 5.067

3.  Elevated levels of clozapine in serum after addition of fluvoxamine.

Authors:  C Hiemke; H Weigmann; S Härtter; N Dahmen; H Wetzel; H Müller
Journal:  J Clin Psychopharmacol       Date:  1994-08       Impact factor: 3.153

4.  AGNP Consensus Guidelines for Therapeutic Drug Monitoring in Psychiatry: Update 2011.

Authors:  C Hiemke; P Baumann; N Bergemann; A Conca; O Dietmaier; K Egberts; M Fric; M Gerlach; C Greiner; G Gründer; E Haen; U Havemann-Reinecke; E Jaquenoud Sirot; H Kirchherr; G Laux; U C Lutz; T Messer; M J Müller; B Pfuhlmann; B Rambeck; P Riederer; B Schoppek; J Stingl; M Uhr; S Ulrich; R Waschgler; G Zernig
Journal:  Pharmacopsychiatry       Date:  2011-09-27       Impact factor: 5.788

Review 5.  The AGNP-TDM expert group consensus guidelines: therapeutic drug monitoring in psychiatry.

Authors:  P Baumann; C Hiemke; S Ulrich; G Eckermann; I Gaertner; M Gerlach; H-J Kuss; G Laux; B Müller-Oerlinghausen; M L Rao; P Riederer; G Zernig
Journal:  Pharmacopsychiatry       Date:  2004-11       Impact factor: 5.788

6.  Individual changes in clozapine levels after smoking cessation: results and a predictive model.

Authors:  J M Meyer
Journal:  J Clin Psychopharmacol       Date:  2001-12       Impact factor: 3.153

7.  ABCB1 and cytochrome P450 polymorphisms: clinical pharmacogenetics of clozapine.

Authors:  Eveline Jaquenoud Sirot; Branka Knezevic; Gina Perla Morena; Sabine Harenberg; Beatrice Oneda; Séverine Crettol; Nicolas Ansermot; Pierre Baumann; Chin B Eap
Journal:  J Clin Psychopharmacol       Date:  2009-08       Impact factor: 3.153

8.  Perazine at therapeutic drug concentrations inhibits human cytochrome P450 isoenzyme 1A2 (CYP1A2) and caffeine metabolism--an in vitro study.

Authors:  Jacek Wójcikowski; Władysława A Daniel
Journal:  Pharmacol Rep       Date:  2009 Sep-Oct       Impact factor: 3.024

9.  Fluvoxamine inhibition and carbamazepine induction of the metabolism of clozapine: evidence from a therapeutic drug monitoring service.

Authors:  M Jerling; L Lindström; U Bondesson; L Bertilsson
Journal:  Ther Drug Monit       Date:  1994-08       Impact factor: 3.681

10.  Omeprazole reduces clozapine plasma concentrations. A case report.

Authors:  A Frick; J Kopitz; N Bergemann
Journal:  Pharmacopsychiatry       Date:  2003-05       Impact factor: 5.788
View more
  3 in total

1.  Cytochrome P450-mediated interaction between perazine and risperidone: implications for antipsychotic polypharmacy.

Authors:  Michael Paulzen; Ekkehard Haen; Christoph Hiemke; Benedikt Stegmann; Sarah E Lammertz; Gerhard Gründer; Georgios Schoretsanitis
Journal:  Br J Clin Pharmacol       Date:  2017-03-02       Impact factor: 4.335

2.  Predicting the risk of drug-drug interactions in psychiatric hospitals: a retrospective longitudinal pharmacovigilance study.

Authors:  Jan Wolff; Gudrun Hefner; Claus Normann; Klaus Kaier; Harald Binder; Katharina Domschke; Christoph Hiemke; Michael Marschollek; Ansgar Klimke
Journal:  BMJ Open       Date:  2021-04-09       Impact factor: 2.692

3.  Pharmacotherapy, drug-drug interactions and potentially inappropriate medication in depressive disorders.

Authors:  Jan Wolff; Pamela Reißner; Gudrun Hefner; Claus Normann; Klaus Kaier; Harald Binder; Christoph Hiemke; Sermin Toto; Katharina Domschke; Michael Marschollek; Ansgar Klimke
Journal:  PLoS One       Date:  2021-07-22       Impact factor: 3.240
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.